[Clinical evaluation of micronomicin for the treatment of postoperative infections in cancer patients].
Micronomicin (MCR, Sagamicin), a new derivative of aminoglycoside, was used in 9 patients with postoperative infection mainly caused by Gram-negative bacilli. A dose of 60-120 mg was intramuscularly administered continuously twice a day for 3-21 days. The therapeutic results were excellent in 2, good in 3, fair in 1 and poor in 2 cases. The assessment was impossible in 1 patient. The effective rate was 62.5%. No side effects were encountered in any cases.
D000328:Adult; D000368:Aged; D000617:Aminoglycosides / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000900:Anti-Bacterial Agents; D001424:Bacterial Infections / Q000188:drug therapy*; D004341:Drug Evaluation; D004352:Drug Resistance, Microbial; D005260:Female; D005839:Gentamicins; D006090:Gram-Negative Bacteria / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications*; D011183:Postoperative Complications / Q000188:drug therapy
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D005839:Gentamicins; C037545:micronomicin